115 related articles for article (PubMed ID: 19628430)
1. Translating biological insights into clinical endpoints in neuro-oncology.
Bredel M
Lancet Oncol; 2009 Oct; 10(10):928-9. PubMed ID: 19628430
[No Abstract] [Full Text] [Related]
2. Mechanisms of evasion to antiangiogenic therapy in glioblastoma.
Rose SD; Aghi MK
Clin Neurosurg; 2010; 57():123-8. PubMed ID: 21280504
[No Abstract] [Full Text] [Related]
3. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.
Narita Y
Jpn J Clin Oncol; 2013 Jun; 43(6):587-95. PubMed ID: 23585688
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab and recurrent malignant gliomas: a European perspective.
Wick W; Weller M; van den Bent M; Stupp R
J Clin Oncol; 2010 Apr; 28(12):e188-9; author reply e190-2. PubMed ID: 20159801
[No Abstract] [Full Text] [Related]
5. Optic neuropathy in patients with glioblastoma receiving bevacizumab.
Chamberlain MC; Raizer J; Schiff D; Sherman JH
Neurology; 2010 Jul; 75(3):289-90; author reply 290. PubMed ID: 20644159
[No Abstract] [Full Text] [Related]
6. Enigma of a rapid introduction of antiangiogenic therapy with bevacizumab in glioblastoma: a new era in the treatment of malignant brain tumours?
Henriksson R; Bergström P; Johansson M; Sandström M
Acta Oncol; 2009; 48(1):6-8. PubMed ID: 18932097
[No Abstract] [Full Text] [Related]
7. 10 Questions about the use of bevacizumab in the management of recurrent malignant gliomas.
Chamberlain MC
Neurologist; 2010 Jan; 16(1):56-60. PubMed ID: 20065801
[No Abstract] [Full Text] [Related]
8. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.
Cohen MH; Shen YL; Keegan P; Pazdur R
Oncologist; 2009 Nov; 14(11):1131-8. PubMed ID: 19897538
[TBL] [Abstract][Full Text] [Related]
9. FDA accelerated approval benefits glioblastoma.
Cloughesy T
Lancet Oncol; 2010 Dec; 11(12):1120. PubMed ID: 21126686
[No Abstract] [Full Text] [Related]
10. Changing end points in breast-cancer drug approval--the Avastin story.
D'Agostino RB
N Engl J Med; 2011 Jul; 365(2):e2. PubMed ID: 21707384
[No Abstract] [Full Text] [Related]
11. Bevacizumab for renal cell carcinoma, glioblastoma, and other solid tumors.
Wilkes GM
Oncology (Williston Park); 2009 Oct; 23(11 Suppl Nurse Ed):54-6. PubMed ID: 19856612
[No Abstract] [Full Text] [Related]
12. Fewer dollars, more sense.
Garfield DH; Hercbergs A
J Clin Oncol; 2008 Nov; 26(32):5304-5; author reply 5305. PubMed ID: 18854564
[No Abstract] [Full Text] [Related]
13. Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma.
Riina HA; Fraser JF; Fralin S; Knopman J; Scheff RJ; Boockvar JA
J Exp Ther Oncol; 2009; 8(2):145-50. PubMed ID: 20192120
[TBL] [Abstract][Full Text] [Related]
14. Ovarian cancer treatments on the horizon.
Schmidt C
J Natl Cancer Inst; 2011 Sep; 103(17):1284-5. PubMed ID: 21852261
[No Abstract] [Full Text] [Related]
15. [Anti-angiogenic strategies in glioblastoma].
Guillamo JS
Rev Neurol (Paris); 2011 Oct; 167(10):662-7. PubMed ID: 21889779
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.
Chinot OL
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1413-27. PubMed ID: 23249106
[TBL] [Abstract][Full Text] [Related]
17. Management of a complex scalp defect.
Plast Reconstr Surg; 2008 Aug; 122(2):623-625. PubMed ID: 18626384
[No Abstract] [Full Text] [Related]
18. Angiogenic inhibition in high-grade gliomas: past, present and future.
Jo J; Schiff D; Purow B
Expert Rev Neurother; 2012 Jun; 12(6):733-47. PubMed ID: 22650175
[TBL] [Abstract][Full Text] [Related]
19. Reputation and precedent in the bevacizumab decision.
Carpenter D; Kesselheim AS; Joffe S
N Engl J Med; 2011 Jul; 365(2):e3. PubMed ID: 21707383
[No Abstract] [Full Text] [Related]
20. Nothing ventured, nothing gained: Treatment of glioblastoma multiforme in the elderly.
Shaw EG
J Clin Oncol; 2004 May; 22(9):1540-1. PubMed ID: 15051758
[No Abstract] [Full Text] [Related]
[Next] [New Search]
